Clinical and Translational Oncology ( IF 3.4 ) Pub Date : 2024-04-01 , DOI: 10.1007/s12094-024-03467-8 Irene González Caraballo , Rocío Martín Lozano , Roberto Jiménez Rodríguez , Javier Soto Alsar , Laura Ortega Morán , Miguel Martín Jiménez , Andrés J. Muñoz Martín
Background
Limited data exist on the prognostic significance of the chronology of VTE in patients with PDAC.
Methods
Medical data and survival characteristics of patients treated for PDAC from 2019 to 2021 were retrospectively reviewed. Early VTE was defined as occurring within the three months of PDAC diagnosis.
Results
197 patients were included, 54 (27.4%) developed a VTE. Early appearance of VTE was associated with worse prognosis: median overall survival (mOS) VTE < 3 months 8.5 months (HR 1.65, 95% CI 1.11–2.46; p = 0.014), mOS VTE > 3 months 12.8 months (HR 0.78, 95% CI 0.39–1.54; p = 0.5) and mOS patients without VTE 11.4 months (95% CI 10.1–15.4). There was no significant association between the patient’s VTE risk according to the Khorana risk score (KRS) (chi2 test p-value = 0.9).
Conclusion
Early VTE is a prognostic factor in PDAC, which may identify a more aggressive subtype.
中文翻译:
静脉血栓栓塞 (VTE) 发生的时间模式对胰腺导管腺癌 (PDAC) 生存的影响
背景
关于 PDAC 患者 VTE 时间顺序的预后意义的数据有限。
方法
回顾性分析 2019 年至 2021 年接受 PDAC 治疗的患者的医疗数据和生存特征。早期 VTE 定义为在 PDAC 诊断后三个月内发生。
结果
纳入的 197 名患者中,54 名 (27.4%) 发生了 VTE。 VTE 的早期出现与较差的预后相关:中位总生存期 (mOS) VTE < 3 个月±8.5 个月(HR 1.65,95% CI 1.11–2.46;p = 0.014),mOS VTE > 3 个月±12.8 个月(HR 0.78,95) % CI 0.39–1.54;p = 0.5),无 VTE 的 mOS 患者为 11.4 个月(95% CI 10.1–15.4)。根据 Khorana 风险评分 (KRS)(卡方检验p值 = 0.9),患者的 VTE 风险之间没有显着关联。
结论
早期 VTE 是 PDAC 的一个预后因素,它可能会识别出更具侵袭性的亚型。